Investing in Psychedelics Stocks
It wasn’t easy to write today’s article.
It hasn’t been easy to do much of anything lately, to be honest.
Mornings are now spent sifting through the news of violence and intolerance.
Afternoons are spent trying to pull me out of a state of depression and frustration long enough to get in a workout.
And at night, after dinner, I take long walks, smoke a little weed, and try to forget about all the shitty things that have happened throughout the day.
This is no way to live.
But neither is feeling sorry for yourself, especially while so many other folks are suffering far worse.
I’m talking about hard-working store owners watching their life’s work get looted by opportunistic criminals...
Reporters getting roughed up by thug cops...
Good cops getting injured and killed while trying to honorably protect and serve...
Peaceful protestors getting arrested and even assaulted for exercising their First Amendment rights.
I have one friend in LA who was arrested and spent two hours in jail for “disturbing the peace.” He was standing in front of his brother’s restaurant, defending it from vandals. He was later told that the police officers who arrested him did so because they were trying to protect him, yet only after he was forcibly removed from the restaurant was his brother’s property damaged.
Not only is this unacceptable, but it’s a violation of the fundamentals of personal sovereignty, i.e., we as individuals are the exclusive owners of our bodies and live
If you're a regular reader of these pages, you know that this is an issue I’m very passionate about, not just as a sovereign citizen, but as an investor, too.
Personal Sovereignty and the Quest for Profits
As you know, I helped a lot of readers make a lot of money in the cannabis space.
This is mostly because I started recommending pot stocks about a year before that market took off. And those who followed my advice pulled in dozens of double-, triple-, and even quadruple-digit gains.
But to be honest, investing in the cannabis space wasn’t just about making a boatload of cash. It was also about defying the demands of every lawmaker that has actively supported the continued prohibition on cannabis.
As an advocate of personal sovereignty, I have no interest in anyone telling me what I can put in my body and how I choose to medicate, especially the government.
So, in defiance of the federal prohibition of cannabis, I’ve not only long enjoyed the relaxing and medicinal benefits of cannabis, but I’ve also enjoyed the financial benefits of investing in the cannabis market back when folks were telling me I could get arrested for such a thing.
Of course, nothing could have been further from the truth. And instead of going to jail, I went to the bank with giant wads of cash and my middle finger held high in the air.
I also feel the same way about psychedelics.
I’ve been telling you about this burgeoning market for the past few months, and it reminds me a lot of the cannabis market. Because once again, in defiance of federal prohibition, I’m enjoying both the medicinal benefits of psychedelics and the financial benefits, too.
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
This Is a Very Big Deal
When I first told my publisher that I was going to start reporting on the psychedelics space he said, “You mean like acid and mushrooms?”
Well, yes, sort of. But not in the way a lot of people thought.
Truth is psychedelics have a long history of being used as medicine.
There's evidence that suggests the use of psychedelic mushrooms goes back to 5000 BCE.
Of course, it’s hard to grasp exactly how they were used back then, but we do know that between 1953 and the early 1970s, the U.S. government spent $4 million (or about the equivalent of $26 million today) to pay for 116 studies of LSD and psilocybin involving over 1,700 subjects.
That’s right, those psychedelics were tested on people with psychedelic disorders ranging from alcoholism to schizophrenia and the results were promising.
There were even calls for more research. That was until President Richard Nixon signed the Controlled Substances Act in 1970, which prohibited the use for almost any purpose, including research of these drugs.
But a lot has changed since then.
And over the past few years, we’ve begun to see a real major shift in how society, the medical community, and the federal government view psychedelics.
Today, the FDA is clearing the way for new psychedelics research, with some companies getting fast-tracked on their clinical trials.
This is a very big deal. And the research that’s now coming out of some of the most prestigious research facilities and universities in the world shows that these drugs are helping with eating disorders, OCD, and major depression –– including cases that didn’t respond to traditional medicine, such as Prozac and Zoloft.
Given that the value of the global behavioral health market is about $200 billion, you can see why I’m so bullish, particularly now that the FDA is on board.
And you should be bullish, too.
But don’t just take my word for it. Look at the data for yourself.
And of course, I’ve also discovered a few publicly traded psychedelics stocks that are already making me a ton of cash. You can read more about those companies here.
To a new way of life and a new generation of wealth...
@JeffSiegel on Twitter
Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's page.
Energy Demand will Increase 58% Over the Next 25 Years
After getting your report, you’ll begin receiving the Energy and Capital e-Letter, delivered to your inbox daily.